The safety of treatment options for acute bacterial skin and skin structure infections
Matteo Bassetti, Maddalena Peghin, Nadia Castaldo & Daniele Roberto Giacobbe
Received 19 Feb 2019, Accepted 16 May 2019, Accepted author version posted online: 19 May 2019, Published online: 13 Jun 2019
Download citation  https://doi.org/10.1080/14740338.2019.1621288 

Select Language​▼
Translator disclaimer
ABSTRACT
Introduction: Acute bacterial skin and skin-structure infections (ABSSSI) may develop in both in-patients and out-patients, possibly with a severe clinical presentation. Since most phase 3 randomized clinical trials have shown non-inferiority in efficacy across different agents, considerations regarding their different safety profiles inevitably play a crucial role in the everyday choice about which of them should be employed for the treatment of ABSSSI.

Areas covered: In this review, the authors discuss the safety profile of different treatment options for ABSSSI.

Expert opinion: The spread of methicillin-resistant Staphylococcus aureus (MRSA) in the last decades has inevitably influenced the therapeutic approach to ABSSSI. Adequate knowledge of the peculiar toxicity profile of each drug active against MRSA is essential for guiding, monitoring and managing adverse events, in turn reducing any unfavorable impact of toxicity on patients’ outcomes. In the next five years, potential toxicity will play a critical role in establishing the best available therapy for each specific patient, together with consideration regarding the possibility of avoiding hospitalization or allowing a switch from intravenous to oral therapy and early discharge.

KEYWORDS: ABSSSI, toxicity, safety, dalbavancin, tedizolid, ceftaroline, delafloxacin, omadacycline